Pharma BD Deal Intelligence
Bayer Diagnostics became the core of a chronically underperforming Siemens/Healthineers Diagnostics unit that took a $1.5B+ impairment and, ~18 years later, Siemens is reportedly trying to sell the whole business for roughly what it originally paid.
Full analysis, sources & comparables →Combined with the DPC acquisition, the Bayer deal would make Siemens the third-largest IVD provider globally with 13% market share, behind Roche (22%) and…
Siemens to buy Bayer's diagnostics arm for EUR 4.2 billion, giving the German conglomerate a leading position in clinical chemistry and entry into molecular…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
In vitro diagnostics; EUR 4.2B; closed early 2007
Bayer Diagnostics became the core of a chronically underperforming Siemens/Healthineers Diagnostics unit that took a $1.5B+ impairment and, ~18 years later, Siemens is reportedly trying to sell the whole business for roughly what it originally paid.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Siemens AG / Bayer Diagnostics (this deal) | 2006 | $5.4B | 38 |
| Siemens AG / Diagnostic Products Corporation | 2006 | $1.9B | 48 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
← Browse all deals · How we score deals
More: 2006 deals